 PhaseBio Pharmaceuticals Inc NASDAQ: PHAS has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of AstraZeneca Plcs NASDAQ: AZN Brilinta ticagrelor and low-dose aspirin. 